137 related articles for article (PubMed ID: 20129123)
1. Rash conclusions from a phase 3 study of cetuximab?
Harrington KJ
Lancet Oncol; 2010 Jan; 11(1):2-3. PubMed ID: 20129123
[No Abstract] [Full Text] [Related]
2. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
3. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab-induced pneumonitis in head and neck cancer patient.
De Vos FY; Driessen CM; Jaspers HC; van Herpen CM; Simons B
Oral Oncol; 2012 Jun; 48(6):e17-8. PubMed ID: 22342570
[No Abstract] [Full Text] [Related]
5. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
[TBL] [Abstract][Full Text] [Related]
6. Acneiform rash secondary to cetuximab plus head and neck radiotherapy.
Mydin AR; Armstrong JG
Radiother Oncol; 2007 Oct; 85(1):171. PubMed ID: 17531339
[No Abstract] [Full Text] [Related]
7. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
Teoh DC; Rodger S; Say J; Hartley A
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
[No Abstract] [Full Text] [Related]
9. StatBite: Radiation therapy plus cetuximab: skin reactions from 71 head and neck cancer patients from 11 institutions in Europe.
J Natl Cancer Inst; 2010 Jan; 102(2):75. PubMed ID: 20054017
[No Abstract] [Full Text] [Related]
10. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
12. Concurrent radio-chemotherapy combination in patients with advanced head and neck squamous cell carcinoma.
Bourhis J
Onkologie; 2005 Oct; 28(10):473-4. PubMed ID: 16285033
[No Abstract] [Full Text] [Related]
13. Cetuximab in squamous cell head and neck carcinomas.
Gebbia V; Giuliani F; Valori VM; Agueli R; Colucci G; Maiello E
Ann Oncol; 2007 Jun; 18 Suppl 6():vi5-7. PubMed ID: 17591832
[TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous reaction during radiation therapy with concurrent cetuximab.
Budach W; Bölke E; Homey B
N Engl J Med; 2007 Aug; 357(5):514-5. PubMed ID: 17671265
[No Abstract] [Full Text] [Related]
15. The future of induction chemotherapy for head and neck squamous cell carcinoma.
Haigentz M; Cohen EE; Wolf GT; Strojan P; Eisbruch A; Ferlito A
Oral Oncol; 2012 Nov; 48(11):1065-7. PubMed ID: 22981388
[No Abstract] [Full Text] [Related]
16. Concurrent chemotherapy and radiation for locally advanced squamous cell cancers: what is the schedule of choice?
Schornagel JH; Verheij M; Bartelink H
Curr Oncol Rep; 2001 Jan; 3(1):1-2. PubMed ID: 11123863
[No Abstract] [Full Text] [Related]
17. Cetuximab plus radiotherapy for head and neck cancer.
Armstrong JG
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710907
[No Abstract] [Full Text] [Related]
18. Rash correlates with tumour response after cetuximab.
Susman E
Lancet Oncol; 2004 Nov; 5(11):647. PubMed ID: 15536688
[No Abstract] [Full Text] [Related]
19. Advances in chemotherapy for head and neck cancer.
Bhide SA; Nutting CM
Oral Oncol; 2010 Jun; 46(6):436-8. PubMed ID: 20400360
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab and radiotherapy for head and neck cancer.
Posner MR; Wirth LJ
N Engl J Med; 2006 Feb; 354(6):634-6. PubMed ID: 16467552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
